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Abstract
Aim Ornithine decarboxylase (ODC) is a modifier of
adenomatous polyposis coli-dependent tumourigenesis.
The G316 > A polymorphism in intron 1 of the ODC
gene lies between two myc-binding domains and alters
the expression of the gene to affect polyamine metab-
olism. This variant may be associated with recurrence of
colorectal adenoma. We examined whether this variant
also modified the susceptibility to sporadic colorectal
cancer (CRC).
Method The G316 > A variant was analysed in a large
(n = 754) CRC case-controlled series of hospital patient
volunteers (n = 627) in the Czech Republic, and the
relationship with cancer risk was estimated by conditional
logistic regression.
Results After adjusting for age and sex, G316 > A was
associated with no decrease in CRC risk for either
heterozygotes [odds ratio 0.98, 95% confidence interval
(CI) 0.77–1.23] or rare allele homozygotes (odds ratio
0.92, 95% CI 0.61–1.37).
Conclusion The G316 > A functional variant in the
ODC gene is unlikely to make much impact on reducing
CRC risk regardless of the reduction in risk found for the
recurrence of colorectal adenoma.
Keywords Colorectal cancer, cancer genetics, association
study, ornithine decarboxylase cancer prevention, colo-
rectal adenoma, aspirin chemoprevention
Introduction
Ornithine decarboxylase (ODC) is the primary rate-
limiting enzyme in the polyamine synthesis pathway by
urea cycle decarboxylation of the amino acids ornithine
and arginine [1]. Polyamines affect several key carcino-
genic processes, and their inhibition is associated with
reduced cell proliferation, increased apoptosis, and sup-
pression of angiogenesis and cancer development in
animal models [2–5]. Expression of ODC and levels of
polyamines are increased in colon cancer and in many
other human epithelial tumours [2,4–6]. Aspirin and
nonsteroidal anti-inflammatory drugs (NSAIDs) exert
chemopreventive effects on colorectal neoplasia, perhaps
partly via their influence on polyamine levels by induction
of polyamine catabolism [2,3]. A common early event in
colorectal tumourigenesis is loss of adenomatous polyp-
osis coli (APC) function and the overexpression of MYC
oncogene, resulting in increased synthesis of ODC, a
target for the transcription factor MYC [7]. Altered
expression of ODC because of its G316A polymorphism
(rs2302615) has been shown to affect polyamine metab-
olism. Two promoter region transcription factor-binding
sites bracket the functional ODC G316A variant, with the
minor allele reducing ODC enzyme expression [8,9].
Thus, the ODC G316A genotype may influence the risk
of development of colorectal neoplasia.
Hubner et al. [10] typed the G316A variant in 546
individuals from a UK prevention trial of aspirin for
colorectal adenoma (CRA) recurrence. They found that
the rare 316AA homozygotes had a nonsignificantly
reduced CRA recurrence risk [relative risk (RR) 0.43,
95% confidence interval (CI) 0.16–1.15], with a sugges-
tion of a possibly lower recurrence risk if exposed also to
aspirin (RR 0.24, 95% CI 0.03–1.71). To help clarify
whether these preliminary results indicated a real effect,
they further pooled their findings with data from the two
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previous USA studies [8,11] so that in 2207 individuals,
those with ODC 316AA genotype were at a significantly
reduced CRA recurrence risk regardless of aspirin use (RR
0.68, 95% CI 0.47–0.99; P = 0.04). Following stratifi-
cation by genotype and aspirin exposure, individuals with
homozygous wild-type or heterozygous genotypes de-
rived modest benefit from aspirin (RR 0.85, 95% CI
0.72–1.01), whereas in those with both ODC 316AA
genotype and aspirin exposure, recurrence risk was halved
(RR 0.52, 95% CI 0.29–0.91; P = 0.02).
To our knowledge, there are no reports of this variant
having been examined as a potential genetic modifier of
colorectal cancer (CRC) susceptibility. We wished to
know whether this variant was also associated with CRC
development and tested this in a large case (n = 754)–
control (n = 627) series from the Czech Republic, a
country that currently has the highest CRC mortality rate
in the developed world [12].
Method
Study population
The study population comprised 754 incident cases with
CRC and 627 hospital-based healthy control subjects.
The cases included 509 colon cancers, 210 rectal cancers
and 35 individuals for whom the cancer site was not
specified. Eligibility criteria for study participation of
cases and control subjects included Czech origin, age
29 years or more and consent to provide biological
samples for genetic analysis. To reduce selection bias,
only those subjects with no previous diagnosis were
included in the study to avoid inclusion of patients with
chronic diseases who may be repeatedly admitted to
hospital and modify their habits because of their disease.
The study cases with positive colonoscopy results for
malignancy, confirmed by histology as colon or rectal
carcinomas, were recruited between September 2004 and
February 2006 from patients visiting nine oncological
departments throughout the Czech Republic (two in
Prague; the others in Benesov, Brno, Liberec, Ples,
Pribram, Usti, Labem and Zlin). During the study
period, sixteen individuals were excluded because they
met the Amsterdam criteria I and II for hereditary CRC
[13,14]. Control subjects were selected during the same
period from individuals undergoing colonoscopy for
various gastrointestinal complaints (macroscopic bleed-
ing, positive faecal occult blood test or abdominal pain of
unknown origin) from five large gastroenterological
departments (Prague, Brno, Jihlava, Liberec and Pri-
bram). Control subjects were selected from those show-
ing a negative colonoscopy for malignancy or functional
bowel disease. The study group were accrued for previous
case-controlled studies investigating the risk of genetic
polymorphisms as recently described [15]. One hundred
and twelve control subjects were excluded from initial
groups because the eligibility criteria were not met or
information on lifestyle and potential risk factors, or
DNA, was not available. In the end, of 739 recruited
control subjects, a total of 627 (84.8%) were included in
the study. The participating subjects gave written
informed consent in accordance with the Declaration of
Helsinki. The design of the study was approved by the
Ethical Committee of the Institute of Experimental
Medicine, Prague.
Study questionnaire
All subjects were interviewed by trained personnel
using a structured questionnaire to determine demo-
graphic characteristics and potential risk factors for
CRC. Study subjects provided information on their
living area, education, lifestyle habits (smoking, drink-
ing, diet, etc.), body mass index (BMI), diabetes,
family ⁄ personal history of cancer and long term (at
least 6 consecutive months) drug use. The median age
of the cases was 61 years (range 27–85) and of the
control subjects 53 years (range 29–91). The charac-
teristics of the study population have been reported
previously [15,16].
Genotyping
Germline DNA was isolated from peripheral leucocytes
within 4 weeks after the blood sample was collected
using the standard proteinase K digestion, phenol ⁄ chlo-
roform extraction and ethanol precipitation and stored at
)80C. ODC G316A genotyping was performed simul-
taneously for cases and control subjects by KBioscience
(Hoddesdon, Hertfordshire, UK) using a competitive
allele-specific PCR system (KASPar). The genotyping
success rate was 97.25%, as there were 38 failed calls (18
for cases and 20 for control subjects) out of the 1381
total attempted reactions. The genotyping assay was
validated using a random 10% of samples as duplicate
quality controls with complete concordance. Samples
with unclear or failed genotype calls were excluded from
the analysis. Details of allele probe sequences are
available on request.
Statistical analysis
The Hardy–Weinberg equilibrium (HWE) was tested for
the ODC G316A polymorphism in the control subjects
using the v2 test. Age- and sex-adjusted unconditional
logistic regression was used to estimate the cancer risk
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association with 95% confidence intervals for the ODC
G316A single nucleotide polymorphism (SNP) (SAS
statistical software, version 9; SAS Institute, Cary, North
Carolina, USA). For all analyses, the reference genotype
was defined as the homozygous (wild-type) allele. All
main effects analysis models were run for colon and
rectum combined (i.e. CRC) as well as separately. Tests
for linear trend were performed using a score variable
with values from 1 to 3 consistent with the genotype
groupings. Using the Quanto software [17], we calcu-
lated that with our present sample size, our study had
80% power (a = 0.05) to detect odds ratio risk reductions
of 0.7 and 0.5 in the dominant and recessive models,
respectively, for the ODC G316A SNP with a minor allele
frequency of 30%.
Results
The frequency for the rare ODC 316A allele is compa-
rable in this Czech control group (0.30) to that in the
UK (0.24) [10] and the US cohorts (between 0.25 and
0.27) [8,11] previously studied for the relationship with
CRA recurrence.
There was no association between the G316A variant
with the risk of CRC in 737 cases and 607 control
subjects (Table 1). Thus, there appeared to be no risk of
cancer with this polymorphism alone as previously
published for adenoma recurrence [10]. The meta-
analysis proposed an association of ODC 316AA with
decreased risk of recurrence of CRA in 2207 individuals
from the USA and UK (RR 0.68, 95% CI 0.47–0.99). We
estimated that heterozygotes of ODC 316GA or 316AA
rare allele homozygotes alone had no significant differ-
ences in their risk for CRC in the Czech population (OR
0.98, 95% CI 0.77–1.23 and OR 0.92, 95% CI 0.61–
1.37, respectively; P for trend = 0.68). Furthermore, no
significant associations were found for colon or rectal
cancers separately, or for men and women or for other
variables, such as BMI, smoking, alcohol consumption or
the presence of polyps.
Discussion
The aim of this study was to determine whether the
functional ODC G316A polymorphism influences sus-
ceptibility to sporadic CRC. We studied the association of
this variant with the risk of CRC using a hospital-based
case-controlled design with 754 patients and 627 control
subjects. There was no significant association between
ODC G316A and risk of CRC for either heterozygotes
(OR 0.98, 95% CI 0.77–1.23) or rare allele homozygotes
(OR 0.92; 95% CI 0.61–1.37). Furthermore, there were
no significant differences between site of cancer (colon or
rectum), sex, BMI, smoking, alcohol or the presence of
polyps.
Studies linking polyamine metabolism and the devel-
opment of CRC precursor lesions have suggested that
this pathway may play an important role in CRC
carcinogenesis [2]. The relationship between ODC
G316A genotype, aspirin use and CRA recurrence has
been investigated in three previous studies. Martinez
et al. [8], in a randomized trial of wheat bran fibre
intervention for CRA recurrence in the USA, reported
that aspirin users homozygous for the minor A-allele of
the G316A variant of the ODC gene were approximately
0.10 times as likely to have an adenoma recurrence as non
aspirin users homozygous for the major G-allele. How-
ever, only 209 (30%) of the 688 individuals genotyped
for ODC G316A reported aspirin use and of those, only
11 harboured the AA genotype. Thus, the confidence
intervals were wide (RR 0.10, 95% CI 0.02–0.66). In a
more pertinent study by Barry et al. [11], the ODC
G316A genotype was analysed from 973 participants in
the Aspirin ⁄ Polyp Prevention Study who were randomly
assigned to placebo or aspirin treatment (81 or 325 mg
daily) and followed for 3 years for the occurrence of new
adenomas. Although no association was found between
ODC genotype and the occurrence of new adenomas
overall, aspirin treatment reduced the adenoma risk in
subjects with at least one A-allele (RR 0.77, 95% CI
0.63–0.95; P = 0.02). In a pooled analysis of these data
with their UK cohort for a total of 2207 individuals,
Hubner et al. [10] reported a significantly decreased risk
of CRA recurrence for ODC 316AA (RR 0.68, 95% CI
0.47–0.99) and an even further decreased risk of
approximately half for ODC 316AA and aspirin intake
(RR 0.52, 95% CI 0.29–0.91). The authors concluded
that the ODC G316A genotype was prognostic for CRA
recurrence and had the potential to be a clinically useful
genetic marker to identify individuals likely to derive the
greatest benefit from aspirin chemoprevention.
Our sample numbers are of the same order as the three
separate adenoma studies combined by Hubner et al.
[10], where a nonsignificant risk reduction was found in












GG 377 303 1.00 (reference) –
GA 297 247 0.98 (0.77–1.23) 0.85
AA 62 57 0.92 (0.61–1.37) 0.66
*Age and sex adjusted.
Ornithine decarboxylase G316A genotype and colorectal cancer risk D. J. Hughes et al.
 2011 The Authors
862 Colorectal Disease  2011 The Association of Coloproctology of Great Britain and Ireland. 13, 860–864
each before the larger, pooled analysis. If this ODC variant
does have a protective effect on CRC risk, the effect is
likely to be more modest than that reported by Hubner
et al. [10], which could be understood in the context that
not all adenomas are at high risk of progressing to cancers.
Our study was not sufficiently powered to test for a
smaller decreased risk for cancers than the adenomas
previously reported [10] (RR 0.68 for 316AA), as there
was an 80% power to detect a reduction in the odds ratio
risk of 0.7 and 0.5 in the dominant and recessive models,
respectively, for the ODC G316A SNP with a minor allele
frequency of 30%. It is possible, therefore, that the ODC
316AA rare allele homozygotes do have a more modest
reduced CRC risk. Together with the biological evidence
of the functional effect of this variant and the similarity in
results from the UK adenoma risk study to our CRC risk
investigation, this would suggest there may yet be a role of
the ODC G316A variant in the adenoma–cancer pathway.
Recently, Zell et al. [18], in a population-based study of
400 cases, reported that the CRC-specific survival hazards
ratio was 2.02 (95% CI 1.17–3.50, P = 0.012) for ODC
GA ⁄ AA genotypes. Therefore, although the ODC G316A
variant may be protective for colon adenoma recurrence
(CRA) and detrimental for survival of colon cancer
(CRC), it is unlikely to play a major role in susceptibility
to CRC development.
We have no data on aspirin use in the Czech
case–control series. There is mounting evidence for a
chemopreventive effect of aspirin and nonsteroidal anti-
inflammatory drugs against the development and recur-
rence of colorectal neoplasia [19–21,2]. However, as
some individuals experience side-effects, the use of these
agents in the prevention of CRC is not currently
recommended [22,23]. As ODC genotype modifies the
response to aspirin treatment for CRA prevention
[8,10,11], the potential of positively modifying aspirin
CRC chemoprevention and selecting individuals geneti-
cally favourable to benefit from this treatment suggests
that it may be worthwhile to test this variant in a much
larger sample size of CRAs and CRCs.
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